CalciMedica is trading 11% up at $0.69 as investors focus on FDA alignment for Auxora’s Phase 2b acute-pancreatitis trial despite a wider-than-expected second-quarter loss.

  • The FDA agreed to new-onset severe respiratory failure as the primary endpoint, and CalciMedica highlighted potential $49 million financing.
  • H.C. Wainwright reiterated a Neutral rating on August 13, 2026.
  • The Nasdaq is up 0.76% and S&P 500 up 0.57%, while FDA and financing developments remain the clearest company-specific catalysts.